Why ADHD is underdiagnosed in women, how hormonal fluctuations affect symptoms, the Monash University findings, medication growth data, and how to get assessed.
Written by the ADHD Provider editorial team. Researched against Australian clinical and government sources. Not medical advice.
What should you do next?
Answer four quick questions to get a practical ADHD care pathway for your situation. No sign-up required.
Find your next stepNot sure if you have ADHD?
Take the free 2-minute ASRS screener based on the WHO Adult ADHD Self-Report Scale. Completely private, no sign-up required.
Take the screening quizADHD has historically been seen as a condition affecting boys — but that view is rapidly being corrected. In clinical settings, boys are diagnosed 3-4:1 compared to girls in childhood (population-based studies find a smaller gap of 2-3:1). This ratio narrows to approximately 1.6:1 in adulthood as more women seek diagnosis later in life.
The most striking data from the AIHW: female ADHD medication dispensing increased fivefold from 4 to 19 per 1,000 between 2018-19 and 2023-24. By 2022-23, female rates surpassed male rates in the 18-24 and 25-44 age groups for the first time — a landmark reversal of the traditional gender pattern.
Between 2020 and 2022, ADHD diagnoses nearly doubled in women aged 30-49, reflecting identification of previously missed cases. This is not a trend or a fad — it is the correction of decades of systematic under-recognition.
A world-first study from Monash University's HER Centre Australia (published in the Journal of Psychiatric Research, 2026) found that the sex-based disparity in ADHD prevalence may reflect systemic misdiagnosis and underdiagnosis of females, rather than a genuine male predisposition to ADHD.
Several factors contribute:
The Monash University study revealed significant hormonal influences on ADHD symptoms that are still poorly understood in clinical practice:
Oestrogen directly affects dopamine signalling in the brain — the same neurotransmitter pathway that ADHD medications target. When oestrogen drops (during the luteal phase, postpartum, and perimenopause), dopamine function decreases and ADHD symptoms can intensify.
Research published in Frontiers in Global Women's Health (2025) documented the "lifelong interplay of hormonal fluctuations with mood, cognition, and disease" in women with ADHD. Undiagnosed women have increased vulnerability to premenstrual dysphoric disorder, postpartum depression, and cardiovascular disease during perimenopause. Women with ADHD are around three times more likely to experience PMDD — see our guide on ADHD and PMDD.
Clinical implication: If your ADHD symptoms fluctuate with your menstrual cycle, this is not "just hormones" — it's evidence that supports an ADHD diagnosis and may require medication dose adjustments at different cycle phases.
Women with ADHD often report:
Late or missed diagnosis in women has documented consequences:
If you suspect you have ADHD:
You deserve an assessment that takes your experience seriously. The surge in women's diagnoses is not because ADHD is trendy — it's because decades of under-recognition are finally being corrected.
A world-first Monash University HER Centre study (Journal of Psychiatric Research, 2026) found the sex-based gap in ADHD prevalence likely reflects systemic misdiagnosis and underdiagnosis of females rather than a genuine male predisposition. Diagnostic criteria were developed largely on boys, and women more often present with inattentive symptoms and effective masking that clinicians historically did not recognise.
Women are diagnosed on average five years later than men, most commonly in their late 30s or early 40s. Between 2020 and 2022, ADHD diagnoses nearly doubled in women aged 30–49 as previously missed cases were identified.
Commonly, yes. 88% of women report ADHD symptom changes across their menstrual cycle, and 97% report changes during menopause. Oestrogen affects dopamine signalling, so when oestrogen drops — in the luteal phase, postpartum, and perimenopause — ADHD symptoms can intensify. If your symptoms fluctuate this way, it is worth raising with your clinician, as it may affect how treatment is managed.
The evidence points the other way. Female ADHD medication dispensing rose fivefold between 2018–19 and 2023–24, and female rates surpassed male rates in the 18–24 and 25–44 age groups for the first time. Researchers characterise this as the correction of decades of under-recognition rather than over-diagnosis.
Ready for an ADHD assessment?
Compare telehealth ADHD assessment providers in Australia for adults and children, and understand referrals and Medicare rebates.
See assessment optionsDisclaimer
This guide is for information only. It is not medical advice. Always consult a qualified healthcare professional for personal medical decisions. Information was accurate at the time of publication but may change.
ADHD medications dispensed over time
Australian Institute of Health and Welfare
www.aihw.gov.au/mental-health/topic-areas/mental-health-pres...Accessed: 2026-02
Australia's Children: Children with mental illness
Australian Institute of Health and Welfare
www.aihw.gov.au/reports/children-youth/australias-children/c...Accessed: 2026-02
Australian Evidence-Based Clinical Practice Guideline for ADHD
AADPA (endorsed by NHMRC, RACGP, RANZCP, APS, RACP)
adhdguideline.aadpa.com.au/Accessed: 2026-02
Browse ADHD specialists across Australia. Compare wait times, fees, and availability.
Find ADHD providers